LOGO
LOGO

Can Chemomab's Nebokitug Become The First Approved Primary Sclerosing Cholangitis Therapy?

By Prabha Kurup   ✉   | Published:   | Follow Us On Google News   | Join Us
scientists 19052026 lt

Chemomab Therapeutics Ltd. (CMMB) is scheduled to make presentations at the Annual Congress of the European Association for the Study of the Liver in Barcelona, Spain, on May 30, 2026.

This clinical-stage biotechnology company is developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Its lead drug candidate is Nebokitug, a first-in-class dual activity monoclonal antibody that neutralizes CCL24, a soluble protein that helps drive the inflammatory and fibrotic pathways central to primary sclerosing cholangitis and other fibro-inflammatory diseases.

Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe Now
Already subscribed? Sign in

For comments and feedback contact: editorial@rttnews.com

Global Economics Weekly Update: May 11 – May 15, 2026

May 15, 2026 15:25 ET
Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.

RELATED NEWS
Latest Updates on COVID-19